Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with ...
ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (SOPH) (Nasdaq: SOPH), an AI technology company ...
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) today announced that the ...
ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company ...
TOKYO and XIAMEN, China, March 27, 2023 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果